» Articles » PMID: 26421474

Vaginal Atrophy of Women in Postmenopause. Results from a Multicentric Observational Study: The AGATA Study

Overview
Journal Maturitas
Specialty Geriatrics
Date 2015 Oct 1
PMID 26421474
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Prevalence of vulvar-vaginal atrophy (VVA) has been always investigated by phone or web interview without any objective evaluation. Objective signs associated with symptoms of VVA are now termed genitourinary syndrome of menopause (GSM). This multi-centric study was performed in order to provide nation-wide data on the prevalence and management of GSM.

Methods: Nine hundred thirteen females, 59.3 ± 7.4 years old asking for a routine gynecological examination were recruited. Diagnosis of GSM was based on patient sensation of vaginal dryness, any objective sign of VVA and a pH > 5.

Results: A 722/913 (79.1%) women were diagnosed with GSM with a prevalence ranging from 64.7% to 84.2%, starting from 1 to 6 years after menopause. Sedentary women were at higher risk of GSM (OR 1.8, 95% CI: 1.3-2.5; p = 0.0005). Recent vaginal infection was more likely in women with GSM (OR 2.48, 95% CI: 1.33-4.62; p = 0.0041). Symptoms reported by women with GSM were vaginal dryness (100%), dyspareunia (77.6%), burning (56.9%), itching (56.6%) and dysuria (36.1%). Signs detected by gynecologists were mucosal dryness (99%), thinning of vaginal rugae (92.1%), pallor of the mucosa (90.7%), mucosal fragility (71.9%) and petechiae (46.7%). Only 274 (30%) of women had had a previous diagnosis of VVA/GSM. These were treated either with no therapy (9.8%), systemic hormone (9.2%), local hormone (44.5%) or local non-hormonal (36.5%) therapy. At the time of our investigation 266 of them (97.1%) still had the disorder.

Conclusions: GSM is a common, under-diagnosed and under-treated disorder. Measures to improve its early detection and its appropriate management are needed.

Citing Articles

Efficacy of a Mixed Wavelength Laser for Vaginal Health in Postmenopausal Women: A Randomized Controlled Trial.

Salinas Pena J, Tameish S, Guilarte Calzada C, Cavalle Busquets P Int J Womens Health. 2025; 17:571-584.

PMID: 40061287 PMC: 11887494. DOI: 10.2147/IJWH.S486323.


Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.

Narutyte R, Zukiene G, Bartkeviciene D Medicina (Kaunas). 2024; 60(10).

PMID: 39459371 PMC: 11509822. DOI: 10.3390/medicina60101584.


Understanding the Benefits of CO Laser Treatment for Vulvovaginal Atrophy.

Jankovic S, Rovcanin M, Tomic A, Jurisic A, Milovanovic Z, Zamurovic M Medicina (Kaunas). 2024; 60(7).

PMID: 39064488 PMC: 11279000. DOI: 10.3390/medicina60071059.


[Resolution of the national interdisciplinary council of experts "High-dose vitamin D (Devilam) in the practice of an obstetrician-gynecologist"].

Andreeva E, Artymuk N, Vesnina A, Zazerskaya I, Karakhalis L, Katkova N Probl Endokrinol (Mosk). 2024; 70(2):103-116.

PMID: 38796767 PMC: 11145572. DOI: 10.14341/probl13465.


The 100 top-cited articles in menopausal syndrome: a bibliometric analysis.

Jin Z, Tian C, Kang M, Hu S, Zhao L, Zhang W Reprod Health. 2024; 21(1):47.

PMID: 38589898 PMC: 11003046. DOI: 10.1186/s12978-024-01770-9.